Business Wire

Landmark Clinical Study Validates Patch-Based Onera Home-Polysomnography System in One of the Largest Sleep Diagnostic Trials of the Decade

Share

Onera Health, a leader in transforming sleep medicine and remote monitoring, today announced the publication of a multicenter validation study of its Onera Sleep Test System (STS) in the Journal of Clinical Sleep Medicine, the official journal of the American Academy of Sleep Medicine. The study demonstrated that the patch-based Onera STS home-polysomnography (hPSG) performs comparably to gold-standard in-lab polysomnography (PSG) for both sleep staging and respiratory event detection.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113111691/en/

A woman is conducting a sleep test (polysomnography) using the patch-based Onera STS hPSG system. (Photo: Business Wire)

The international multicenter study was managed by an independent Clinical Research Organization and involved the analysis of 206 participants across seven clinical sites in Germany and a US-based core laboratory at Johns Hopkins University. The study found high concordance between the Onera STS and traditional PSG across essential sleep variables and key respiratory parameters, as well as substantial epoch-by-epoch agreement in sleep staging and comparable inter-scorer reliability between the two systems, which is essential for physicians to make accurate diagnoses and treatment decisions in sleep medicine.

"Our rigorous multicenter validation study provides robust evidence that the Onera Sleep Test System performs comparably to traditional in-lab polysomnography for sleep staging and respiratory event detection," said Dr. Christian Viniol, MD, Ph. D, lead author and Head of Sleep Medicine at University Hospital Marburg, Germany. "This validation is crucial as we face increasing demand for sleep studies alongside increasing resource constraints. The proven accuracy of Onera’s product will significantly improve access to comprehensive sleep diagnostics, potentially transforming our approach to diagnosing and treating sleep disorders on a larger scale."

"We are thrilled with the successful completion of this comprehensive validation study," said Ruben de Francisco, Founder and CEO of Onera Health. "This validation is a critical milestone in our mission to make the gold-standard sleep test, polysomnography or PSG, available at the patient’s home. The results clearly demonstrate that our innovative, patch-based technology can deliver the level of accuracy needed for a comprehensive hPSG sleep test, with an accuracy that is equivalent to that of traditional in-lab PSG."

"These results represent an important milestone in our journey toward more accessible and personalized sleep medicine. The Onera technology enables high-quality sleep assessment in the patient's natural environment, opening new possibilities for longitudinal monitoring and improved assessment of treatment outcomes. This capability may fundamentally transform the future of sleep disorder diagnosis and treatment evaluation in the future," added Dr. David P. White, Professor of Medicine, Part Time at Harvard Medical School, Boston, United States, and Member of the Medical Advisory Board at Onera Health.

The wireless, patch-based Onera STS hPSG addresses critical challenges in sleep medicine by providing a viable alternative to traditional in-lab polysomnography. Its comparable performance in sleep staging and respiratory event detection, coupled with simplified application, significantly increases access to high-quality, comprehensive sleep assessments.

This landmark validation study is part of Onera Health's comprehensive clinical evidence generation program, demonstrating the commitment to rigorous scientific validation of Onera’s technology. Additional studies are currently ongoing across multiple centers and healthcare settings, which will further validate the clinical utility and real-world impact of Onera’s home Polysomnography solution. This evidence generation strategy reflects Onera’s dedication to advancing sleep medicine through high-quality clinical research.

The study, entitled 'Clinical validation of a wireless patch-based polysomnography system', is published in the Journal of Clinical Sleep Medicine and can be accessed online at https://jcsm.aasm.org/doi/10.5664/jcsm.11524.

About Onera

Onera Health is a leader in transforming sleep medicine and remote monitoring. Their breakthrough diagnostic solutions and services are poised to help millions of people struggling with sleep-related ailments while also impacting other medical fields by monitoring various chronic conditions, ultimately improving the health and quality of life of patients worldwide. The company’s innovative solutions provide comprehensive sleep test data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the U.S. For more information, go to onerahealth.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250113111691/en/

Contacts

For additional information or media inquiries, please contact:
Swea Ann Hagenhoff
Sr. Branding and Communications Specialist
Onera Health
media@onerahealth.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alphemy Capital appoints Barry Schachter as Head of Portfolio Risk Management14.1.2025 22:26:00 EET | Press release

Alphemy Capital S.A. (“Alphemy Capital”), a leading digital asset and blockchain investment manager, has appointed Barry Schachter as Head of Portfolio Risk Management. Schachter formally joined the firm in January 2025 after nine months as its Risk Management Advisor, where he worked closely with the investment team in developing new tools and analytics to enhance Alphemy Capital’s existing risk management framework. Schachter brings more than 20 years’ experience in executive risk management roles at top hedge funds, including Caxton, SAC, Balyasny, and Moore. An investment industry veteran, he has been instrumental in designing, implementing, and leading risk management functions at multiple firms, for some of these as a member of the pre-launch team. “I am excited to have Barry at Alphemy Capital in this senior leadership role,” said Roman Khrushch, CEO of Alphemy Capital. “Barry’s truly unparalleled combination of experience and expertise strengthens our team in multiple ways.” Ma

Zayed Sustainability Prize Celebrates Innovators Driving Global Progress at 2025 Awards14.1.2025 22:15:00 EET | Press release

Today, His Highness Sheikh Mohamed bin Zayed Al Nahyan, President of the UAE, recognised the 2025 winners of the Zayed Sustainability Prize. Celebrating the transformational impact of 11 pioneering organisations and high schools from across the world, the Prize reflects the UAE’s commitment to fostering scalable solutions to global challenges and empowering communities in their pursuit of sustainable prosperity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114367660/en/ Zayed Sustainability Prize celebrates innovators driving global progress at 2025 Awards (Photo: AETOSWire) In a Ceremony held during Abu Dhabi Sustainability Week (ADSW) and attended by 11 Heads of State, Ministers, and business leaders, H.H. Sheikh Mohamed bin Zayed awarded the winners for their remarkable achievements, encouraging continued innovation in every corner of the globe. H.H. Sheikh Mohamed bin Zayed said: “The UAE remains steadfast in its co

Cabot Properties Expands European Leadership Team to Capitalize on Increasingly Attractive Logistics Property Market14.1.2025 19:07:00 EET | Press release

Cabot Properties, a leading investor, developer and operator of logistics properties throughout the United States, Europe and Asia Pacific, today announced that it has expanded its European leadership team as it continues to grow its presence across the region. The firm has hired Thomas Schellhorn as Vice President to oversee asset management for Cabot’s operations in Germany and the Netherlands. In this role, he will be responsible for leasing and capital improvement programs and will report to Jed Raymond, Senior Director and Head of Asset Management for UK and Europe. Justin Harvey, Managing Director and Head of UK and Europe, will relocate to Cabot’s London office to continue leading the firm’s overall strategy and operations across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114998320/en/ Thomas Schellhorn, Vice President, Asset Management, Germany and The Netherlands (Photo: Business Wire) “Justin has bee

Verimatrix Announces Release of DVB ReAccess Over-the-Air CAS Retrofit Solution14.1.2025 18:45:00 EET | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX, FR0010291245), the leader in powering the modern connected world with people-centered security, today announced general availability of its new DVB ReAccess solutions that serves as a uniquely powerful over-the-air (OTA) Conditional Access System (CAS). The solution also provides users with added peace of mind following the recent completion of Cartesian’s Farncombe Security® Audit. DVB ReAccess addresses a notable hurdle for one-way networks such as broadcast satellite providers that lack bidirectional handshakes to identify and authenticate client devices authorized to decrypt content. In one-way networks, the security of content relies almost exclusively on the resistance and resilience of the CAS, the most secure of which have a client software deeply anchored within the device’s hardware, leveraging a number of security features provided by the chipset. Consequently, once a CAS is integrated on a device, it’s typically very challe

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome14.1.2025 18:19:00 EET | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. If granted marketing authorization, trofinetide will be the first and only approved therapy for Rett syndrome in the European Union (EU). Trofinetide is already approved in the United States and Canada for Rett syndrome in adults and pediatric patients two years of age and older. “This application underscores our continued dedication to the Rett community, and our commitment to making a meaningful impact for people living with Rett syndrome and their caregivers in the EU, who currently have no approved treatment options specifically for this condition,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “We look forward to working with the EMA to address this unmet need in the hopes of potentiall

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye